Clinical Trials Browser

Anus Neoplasms, Condylomata Acuminata

NCT00092534 2025-08-01

FUTURE II

Phase 3 Completed

12,167 enrolled 23 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT06465914 2024-12-12

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Phase 3 Active not recruiting

9,000 enrolled

GastrointestinalGenitourinary

Anus Neoplasms, Condylomata Acuminata, Penile Neoplasms

NCT04422366 2024-06-07

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Recruiting

8,000 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT04895020 2024-04-17

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Phase 3 Recruiting

1,200 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05027776 2024-04-17

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Phase 3 Recruiting

1,348 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Papillomavirus Infections

NCT05372016 2023-11-24

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Completed

1,200 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05584332 2023-07-21

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Terminated

3,131 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT05314023 2023-01-19

V503-053

Phase 3 Active not recruiting

1,590 enrolled

Condylomata Acuminata

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Phase 3 Active not recruiting

2,750 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT04425291 2022-02-25

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Completed

1,680 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT05156541 2021-12-14

ING-HPV-1

Phase 3 Completed

30 enrolled

Condylomata Acuminata, Papillomavirus Infections

NCT03546842 2020-02-25

V503-017

Phase 3 Completed

201 enrolled 11 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections, Adenocarcinoma in Situ

NCT03158220 2019-11-21

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Phase 3 Completed

1,212 enrolled 15 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT01047345 2018-11-27

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Phase 3 Completed

924 enrolled 16 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT01651949 2018-11-27

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

Phase 3 Completed

2,520 enrolled 13 charts

Gastrointestinal

Anus Neoplasms, Condylomata Acuminata

NCT01245764 2018-11-14

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Phase 3 Completed

250 enrolled 20 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00090285 2018-08-23

V501-020

Phase 3 Completed

4,065 enrolled 27 charts

Condylomata Acuminata

NCT00092482 2017-03-22

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Phase 3 Completed

3,882 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00517309 2017-03-22

FUTURE

Phase 3 Completed

1,877 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00092521 2015-09-25

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

Phase 3 Completed

5,759 enrolled 10 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00092495 2015-01-13

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Phase 3 Completed

3,055 enrolled 25 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT01111344 2012-05-08

Glizigen-Viudid-External Anogenital Warts in Children and Adolescents

Phase 3 Completed

76 enrolled

Condylomata Acuminata

NCT00735462 2011-07-20

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

Phase 3 Completed

511 enrolled 10 charts

Condylomata Acuminata

NCT00674739 2011-05-24

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

Phase 3 Completed

470 enrolled 11 charts

Condylomata Acuminata

NCT00449982 2007-03-21

Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

Phase 3 Completed

480 enrolled

Condylomata Acuminata

Clinical Trials

V503-064

FUTURE II

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

V503-053

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

ING-HPV-1

V503-017

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

V501-020

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

FUTURE

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Glizigen-Viudid-External Anogenital Warts in Children and Adolescents

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts